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Abstract: A high prevalence of hepatic pathology (in 17 of 19 cases) was reported in post-mortem
(PM) examinations of COVID-19 patients, undertaken between March 2020 and February 2021 by a
single autopsy pathologist in two English Coronial jurisdictions. The patients in our cohort demon-
strated high levels of recognised COVID-19 risk factors, including hypertension (8/16, 50%), type
2 diabetes mellitus (8/16, 50%) and evidence of arteriopathy 6/16 (38%). Hepatic abnormalities
included steatosis (12/19; 63%), moderate to severe venous congestion (5/19; 26%) and cirrhosis
(4/19; 21%). A subsequent literature review indicated a significantly increased prevalence of steato-
sis (49%), venous congestion (34%) and cirrhosis (9.3%) in COVID-19 PM cases, compared with a
pre-pandemic PM cohort (33%, 16%, and 2.6%, respectively), likely reflecting an increased mortality
risk in SARS-CoV-2 infection for patients with pre-existing liver disease. To corroborate this observa-
tion, we retrospectively analysed the admission liver function test (LFT) results of 276 consecutive,
anonymised COVID-19 hospital patients in our centre, for whom outcome data were available. Of
these patients, 236 (85.5%) had significantly reduced albumin levels at the time of admission to
hospital, which was likely indicative of pre-existing chronic liver or renal disease. There was a strong
correlation between patient outcome (length of hospital admission or death) and abnormal albumin
at the time of hospital admission (p = 0.000012). We discuss potential mechanisms by which our
observations of hepatic dysfunction are linked to a risk of COVID-19 mortality, speculating on the
importance of recently identified anti-interferon antibodies.
Keywords: COVID-19; SARS-CoV-2; post-mortem; hepatic pathology; interferon dysregulation; liver
function tests; steatosis; cirrhosis; autopsy; pathology
1. Introduction
Since its discovery in Wuhan in December 2019, the novel coronavirus SARS-CoV-2
has caused a global pandemic [1,2], resulting in over 183 million worldwide cases and over
3.9 million fatalities [3]. Most cases are mild and self-limiting, with symptoms such as
pyrexia, cough, anosmia, and myalgia [4,5]. Risk factors for more severe disease have been
identified, including increasing age, obesity, type 2 diabetes, hypertension, cardiovascular
disease and chronic respiratory disease [6–8]. However, the interplay between these factors,
potential causal relationships, and their roles in infection, disease progression and mortality,
is not fully understood.
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Careful analysis of past cases of severe COVID-19 can inform the global collaborative
effort to understand precisely why severe disease develops in a minority of patients. Post-
mortem (PM) studies are highly relevant to this process. The SARS-COV-2 virus gains
access to host cells via the ubiquitously expressed ACE-2 receptor [9–11], and thereby has
the potential to invade and affect any organ system. Moreover, severe cases are known to
result in systemic immune and coagulation dysregulation, with reported consequences
including acute respiratory distress syndrome (ARDS) [12,13] thrombosis [14], and damage
to the cardiovascular, renal and hepatobiliary systems [15]. PM studies enable examination
of these broad consequences of COVID-19, as well as allowing pre-existing, but potentially
undetected, pre-/comorbidities to be described. A better understanding of pre-/comorbid
risk factors and the mechanisms by which they contribute to severe disease could enable
more effective treatment, as well as risk mitigation, providing a more robust evidence base
for targeted public health measures, such as the shielding of particular groups.
This report summarises the findings of 22 PM examinations carried out in two English
Coronial jurisdictions between March 2020 and February 2021. The deceased individuals
had either an antemortem confirmation of COVID-19 or a compatible history, together
with PM histopathological changes in the lung consistent with COVID-19. We note a high
frequency of likely pre-existing liver disease, which is hitherto largely undescribed, and
question whether this might represent an asymptomatic premorbid risk factor for severe
COVID-19.
2. Methods
Twenty-two clinical autopsies of cases with confirmed or likely COVID-19, undertaken
by an experienced consultant autopsy pathologist (E.J.S.) and carried out in two English
Coronial jurisdictions between March 2020 and February 2021, were analysed and the
findings summarised. The liver was only examined in 19/22 cases. As this was an
anonymised audit project, neither specific ethical approval nor consent from next-of-kin
were required.
To place these results in the context of the global COVID-19 pandemic, a literature
review was conducted on PubMed, Embase and Ovid MEDLINE, in accordance with the
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines [16], in order to identify similar reports of PM examinations in COVID-19. All
English-language articles published before 3 August 2020 were eligible for inclusion and
antemortem studies were excluded. The search strategy was to search for the following set
of terms: 1. Coronavirus OR (corona virus) OR COVID-19 OR SARS-CoV-2; 2. Postmortem/
OR autopsy/; 3. 1 AND 2. Two reviewers (Y.H. and J.S.) screened the titles and abstracts
of the search results. Disagreements over the inclusion of papers were discussed by all
authors until mutual agreement was reached (Figure 1). The macroscopic and microscopic
findings for each organ system were extracted and summarised.
To investigate liver pathology, the number of post-mortem studies identified by
a literature search that specifically mentioned liver findings was recorded and a more
detailed summary of these hepatic findings was produced. Next, we sought to investigate
the hypothesis that hepatic pathology may be more prevalent among individuals who go
on to die as result of COVID-19 than among those who die from other causes. Pre-pandemic
post-mortem studies were identified and data on the frequency of key hepatic pathologies
seen at autopsy (steatosis, cirrhosis, and venous congestion) were extracted. The total
frequency of these hepatic pre-pandemic post-mortem abnormalities was calculated and
compared to their frequency in COVID-19 post-mortem cases, including our own, reported
here. Statistical analysis was performed using the Chi-squared test on Microsoft Excel.
Under ethical approval IRAS 162057, retrospective analysis of admission liver function
test (LFT) results, specifically alanine transaminase and albumin, was undertaken for
276 consecutive, anonymised COVID-19 positive inpatients in Addenbrooke’s Hospital,
Cambridge, between 1 March 2020 and 3 June 2020, for whom outcome data were known.
All patients had a positive Eurofins PCR-based test for SARS-CoV-2 within the 10 days
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preceding admission or on the date of admission. Abnormal LFT results were defined as
ALT > 40 iµ/L and albumin < 35 g/L. The length of hospital stay in days and mortality were
also recorded. A Chi-squared test was used to compare the frequency of abnormal results
between patient groups, which were stratified by stay length or mortality. A one-way
ANOVA was performed to determine the correlation between admission LFT data and stay
length or mortality. A p-value of <0.05 was considered statistically significant for all tests.
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3. Results
The findings of the 22 PM cases (14 male; 8 female) are detailed in Table 1. Notable
features on external examination were cyanotic fingernails (15/19; 79% (3 cases could
not be assessed due to racial pigmentation)) and a hyperinflated chest (6/22; 27%). The
diagnosis of COVID-19 was made either by antemortem or PM viral PCR, or on the basis
of characteristic PM histopathological findings, including diffuse alveolar damage/acute
respiratory distress syndrome spectrum changes and lymphohistiocytic infiltration with
viral cytopathic effects, but generally few neutrophils (Figure 2A–C). The age range in
years was 48–94, with a mean age of 70. The primary cause of death stated on the UK death
certificate, as given by the pathologist, was of a respiratory nature in 19 cases (‘ARDS, viral
pneumonia’= 3; ‘acute bacterial pneumonia’ = 3; ‘Viral pneumonia with features consistent
with COVID-19′ = 2; ‘COVID-19 infection’ = 7; ‘pulmonary thromboembolism’ = 4). The
primary cause of death in two cases was cardiac arrhythmia, and in one case it was hypoxic
brain injury and multiorgan failure. COVID-19 infection, either probable or confirmed,
was specifically mentioned in the causes of death in 19 of the 22 cases, under part 1a in
Diagnostics 2021, 11, 1703 4 of 21
11 cases, part 1b in 3, part 1c in 4 and part 2 in 1. The three cases in which COVID-19
infection is not mentioned on the death certificate were undertaken in March 2020, at
the start of the pandemic in the UK, when COVID-19 testing was not widely available
and pathologists were less familiar with COVID-19 histopathological findings in the lung
and, thus, a description of the lung findings (either ARDS or organising pneumonia) was
included on the death certificate. Re-review of these cases in view of subsequent detailed
publications describing COVID-19 lung pathology [17–51] indicated that the cause of death
was COVID-19.
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Table 1. Key findings of 22 post-mortem examinations carried out on confirmed or suspected cases of COVID-19 infection between March 2020 and February 2021. Centiles for heart
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Key: + = mild, ++ = moderate, +++ = severe. For coronary artery stenosis, mild = <20%, moderate = >50% and severe = >70%. The term (mic) denotes microscopic findings. Abbreviations in table (alphabetical
order): A-C = Afro-Caribbean; AF = atrial fibrillation; AKI = acute kidney injury; ARDS = acute respiratory distress syndrome; AM = antemortem; BMI = body mass index; BPu = bronchopneumonia; C = (hepatic)
cirrhosis; CA = coronary artery; CABG = coronary artery bypass grafting; CHF = congestive heart failure; CKD = chronic kidney disease; Cn = Caucasian; COPD = chronic obstructive pulmonary disease; DM
= diabetes mellitus; DVT = deep vein thrombosis; F = female; GI = gastrointestinal; Histol = histology; HTN = hypertension; IBS = irritable bowel syndrome; IgG MGUS = immunoglobulin G monoclonal
gammopathy of undetermined significance; IHD = ischaemic heart disease; ILD = interstitial lung disease; L0 = lymphocytes; LVH = left ventricular hypertrophy; M = male; MCCD = Medical Certificate of Cause
of Death; MF = myocardial fibrosis; MH = myocyte hypertrophy; MI = myocardial infarction; MNI = mononuclear (myocardial) infiltration; n/a = not applicable; n/e = not examined; N.S. = nil significant;
OPu = organising pneumonia; PE = pulmonary embolism; PF = pulmonary fibrosis; pHTN = pulmonary hypertension; Pl adhes = pleural adhesions; Pl eff = pleura; effusion; PL0 = portal lymphocytic infiltrate;
PM = postmortem; PO = pulmonary oedema; PTE = pulmonary thromboembolism; Pu = pneumonia; RHF = right-sided heart failure; RNA = ribonucleic acid; S(ma) = (hepatic) macrovesicular steatosis;
S.D. = standard deviation; T2DM = type 2 diabetes mellitus; UTI = urinary tract infection; VC =venous (hepatic)congestion (passive in nature).
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As these were coronial (medicolegal) autopsies, the quantity and quality of clinical
information available, such as past medical history, depended on the deceased’s recorded
interactions with health services. For the 16 cases where the past medical history was
available, 16 cases had pre-existing comorbidities known to increase the risk of severe
COVID-19 [6–8,53], including diabetes (n = 8), hypertension (n = 8), cardiovascular dis-
ease (n = 6), chronic kidney disease (n = 4) and interstitial lung disease (n = 1). Likewise,
established potentially fatal complications of SARS-CoV-2 infection were observed mi-
croscopically, including ARDS (n = 17/21 cases undergoing histological examination),
thromboembolism (n = 8/21) and consequent bacterial pneumonia, described either as
the presence of bronchopneumonia or neutrophils, superimposed on the ARDS picture
(n = 9/21) [12–14,54] (Figure 2A–C). The most pertinent cardiovascular findings were
cardiomegaly and ventricular dilatation, which is in keeping with hypertension and cardio-
vascular disease being key risk factors for severe disease. Of the 22 patients, 15 (68%) had
cardiomegaly, which we chose to define as >90th centile for gender and body weight [52],
with 12/22 (55%) cases above the 97th centile. Twenty (91%) patients had moderate or
severe ventricular dilation.
Notably, no patients had a formal antemortem diagnosis of liver disease, yet hepatic
abnormalities were detected at PM in 17/19 (89%) of the cases in which the liver was
examined (Figure 2D–F; Table 1). The liver was not examined in three cases because, early
in the pandemic, limited autopsy examinations were undertaken due to fears about risks
to pathologists and anatomical pathology technicians. Only the heart and lungs were
examined in these three cases. Thirteen out of nineteen cases (68%) demonstrated likely
longstanding liver pathology in the form of steatosis (nine cases without cirrhosis; three
cases with cirrhosis) and cirrhosis without obvious steatosis (one case.) Additional hepatic
abnormalities detected included four cases showing passive venous congestion without ob-
vious evidence of either steatosis or cirrhosis, two cases showing passive venous congestion
with steatosis, while one individual had steatosis, cirrhosis and passive venous congestion.
In five of these seven cases with passive venous congestion, there was autopsy evidence
of significant ischaemic heart disease, with one case additionally having interstitial lung
disease, indicating that the passive venous congestion was likely to be longstanding. In
one case without any macroscopically obvious liver pathology, a microscopically iden-
tified portal tract lymphocytic infiltrate was present and, given the patient’s history of
intravenous drug use, hepatitis C was clearly a possibility, but, by the time the histological
material was prepared for the pathologist’s review, no suitable sample for hepatitis testing
remained. In this case, the liver also appeared pale and acutely ischaemic macroscopically
as a consequence of shock, due to a large, multifocal gastrointestinal haemorrhage, which
was assumed to be a consequence of enterocyte infection with SARS-CoV-2.
Table 2 [17–51,55–69] summarises the key macroscopic and microscopic findings
derived from published PM studies of COVID-19 and indicates that our findings were in
keeping with those of other autopsy studies. Amongst these studies, there was considerable
heterogeneity in terms of pathological findings, most notably the presence or absence of
myocarditis, vascular inflammation and /or microthrombi. A total of 42% of the studies
specifically examined the hepatic system, giving heterogeneous results, with variable
frequencies of cirrhosis/ fibrosis, steatosis, venous congestion, inflammatory changes and
hepatocyte injury or death (Table 3) [17–51,55–69].
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Table 2. Post-mortem pathology in COVID-19 described in published studies.
System Site/Feature Key Findings (Positive and Negative)
Cardiovascular
Pericardium Effusion [17,19,55]; fibrinous pericarditis [23]
Heart weight & chambers Cardiomegaly/chamber hypertrophy [18,19,21,23–27,34]Chamber dilatation [17–22,26]
Myocardial ischaemia





Chronic inflammatory cells without myocarditis
[18,23,26,36]
Atherosclerosis Significant coronary artery atherosclerosis [23]Atherosclerosis, not otherwise specified [22,24,27–29]
Vascular abnormalities
(multiple systems)
Vasculitis Endothelialitis of heart, small bowel, lung [55]; fibrinoidalteration (exact location not specified) [35]
Microthrombi Lung, glomeruli, spleen, heart, dermis, testis, liversinusoids [35]
Macroscopic thromboemboli Deep venous [27]; pulmonary [18,21,29,38]
Respiratory
Pleura and pleural cavity
Effusions [17,19,21,23,25,32,41,43]; pleuritis [51]; thickening
[17,19,21]; adhesions [23,30]
Subpleural petechiae [36]




Haemorrhage [27,36]; oedema [23]; necrosis [27]; collapse
[43]
New fibrosis, extensive [23,38]
Pre-existing structural lung disease [23,25,27]
Airways
Upper airway inflammation [23,27,29,40,51,67]
Bronchial inflammation [21,22,28,29,40,44,45,55] with
mucus [19,26,30,40,46]





Diffuse alveolar damage/ARDS spectrum [17–24,26–51]
Fibrosis [25,43,48,51]
Lobar pneumonia [23]
Chronic inflammatory cell infiltrate
[17–19,22–24,27–30,33,34,39,41,42,47,49,56]






Small vessel fibrinoid necrosis [34]
Severe endothelial injury with intracellular virus by EM
[20,39]
Neutrophilic & exudative capillaritis
[18,20–22,29,32,33,45–48]
Lymphocytic vasculitis [51]
No vasculitis [49]; no thrombi [23]
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Table 2. Cont.
System Site/Feature Key Findings (Positive and Negative)
Kidneys
Vascular
Pallor/ shock/ ischaemia [24,27,41,61,62]; infarction
[24,27,62]; medullary congestion [41]
Arteriolar & arterial fibrin thrombi [31,61]
Microthrombi in glomeruli1 [7,22,24,31,35,61]
Glomerular capillary congestion [51,61]
Peritubular capillary congestion [51,61]
Tubulo-interstitial
Acute tubular injury/ necrosis [21,24,28,35,42,44,51,60–62]
ACE2 expression upregulated in proximal tubules [61]











Red pulp infarction [50]; red pulp lymphoplasmacytic
infiltrate [18]
Atrophy [18,21,28,35,37,50]; white pulp hyperplasia [50]
Haemophagocytosis [17,50]
Acute splenitis (concurrent bronchopneumonia) [24]
Lymph nodes & bone marrow
Hilar & mediastinal lymphadenopathy [21,24,50] & with
haemophagocytosis [50]
Lymph node haemophagocytosis (site not stated) [17]; no
lymph node haematophagocytosis [50]
Bone marrow haematophagocytosis [49]; no bone marrow
haematophagocytosis [50]
Adrenal glands
Shocked appearance [25]; microscopic haemorrhage [37]; zona reticularis hyperplasia [21]
Acute fibrinoid arteriolar necrosis [64]
No adrenal abnormalities [50]
Table 3. Post-mortem hepatic pathology in COVID-19 described in published studies.
Pathology Ref & Frequency WhereAscertainable Applied Interpretation
Fibrosis
Periportal 3/11 [21] 29/48 [59]
Pre-existing hepatic disease
Incomplete septa 3/11 [21] 8/48 [59]




Centrilobular 1/1 [22] 12 [32]
Likely pre-existing
alcoholic/non-alcoholic (e.g., obesity or
diabetes-related) fatty liver disease
Macrovesicular only 1/4 [34] 1/7 [33]1/48 [59]
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Right-sided cardiac failure (may be
secondary to effects of COVID-19 or












Massive 1/11 [21] Seen in severe hepatic injury due to avariety of causes




May be seen in acute viral hepatitis




Periportal necrosis may be due to
interface hepatitis. Centrilobular
necrosis is attributable to
hypoperfusion injury but may also be














Non-specific finding secondary to
hepatocyte injury
Syncytial hepatocytes 2/2 [43] Non-specific finding secondary tohepatocyte regeneration





Seen in a variety of pathologies
including resolving acute hepatitis,







May be seen in acute viral hepatitis
(CMV, EBV), autoimmune hepatitis,














Seen in human cytomegalovirus (CMV)
infection but may also be seen in other
settings, such as ascending cholangitis
and seeding from a septic source
Not specified 0/1 [36]
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Table 3. Cont.















Not specified 7/7 [33]0/1 [36] 9/10 [35]




Dilatation 7/7 [33] 2/4 [34]
Seen in hypercoagulability syndromes
and
venous flow abnormalities
Intrasinusodal fibrin thrombi 1/10 [35]0/2 [43] 13/48 [59]
Non-specific finding implicated in the





Cholestasis 8/11 [21]2/7 [33] 0/2 [43]
Non-specific finding that may be seen
in sepsis amongst other aetiologies
Ductular reaction with lymphocytic
inflammation 7/11 [21] Non-specific finding secondary to acute
biliary obstructionDuctular reaction without
inflammation 1/11 [21]
Haemophagocytosis 1/4 [20] 0/4 [50]
Non-specific finding that may be seen
in sepsis and other systemic
haemophagocytic disorders
Thrombosis 1/11 [21]35/48 [59]
Implies a pro-coagulant state
(systemic/ localised)
Macroscopic impression of liver shock 3/12 [27] NS/80 [29] Secondary to hypoperfusion





0/4 [50] Significance uncertain
The prevalence of steatosis, venous congestion and cirrhosis was compared between
published COVID-19 PM cohorts (Table 3), our PM cohort (Table 1) and pre-pandemic
PM cohorts (Table 4) [17–51,55–76]. There was a very significant increase in steatosis and
cirrhosis among patients dying of COVID-19 in our study and in published COVID-19
autopsy studies, compared with pre-pandemic PM cohorts. While there was no significant
increase in the frequency of venous congestion between our COVID-19 patients and pre-
pandemic PM cohorts, there was a statistically significant difference between the frequency
of venous congestion in published COVID-19 autopsy studies and the frequency in pre-
pandemic PM cohorts.
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Table 4. Prevalence of steatosis, venous congestion and cirrhosis in pre-pandemic and COVID-19 post-mortem co-
horts. Compared with pre-pandemic PM cohorts, our COVID-19 PM cohort had a significantly higher frequency of
steatosis [X2(1, n = 2086) =7.72 p < 0.005] and cirrhosis [X2(1, n = 1862) = 24.22 p < 0.001], but not venous congestion
[X2(1, n = 360) = 1.55 p > 0.05]. When aggregating our study with those of other published COVID PMs there was a signifi-
cantly higher frequency of steatosis [X2(1, n = 2250) =22.24 p < 0.00001], cirrhosis [X2(1, n = 1959) =27.55 p < 0.00001] and
venous congestion [X2(1, n = 520) = 21.07 p < 0.00001] compared to pre-pandemic PM cohorts. Considering COVID-19
published studies only, compared with pre-pandemic PM cohorts, there was a significantly higher frequency of steatosis
[X2(1, n = 2231) =16.83 p < 0.0001], cirrhosis [X2(1, n = 1940) = 14.88 p < 0.001] and venous congestion [X2(1, n = 501) =21.49
p < 0.00001].
PM Cohort Steatosis VenousCongestion Cirrhosis















Aggregate data derived from all pre-pandemic PM studies detailed
in the rows below 682/2067 (33%) 53/341 (16%) 47/1843 (2.6%)






Non burn trauma [76] 108/22448% Not measured
Multiple causes: trauma (35%), acute myocardial infarction (30%),
opiate overdose (13%), cerebrovascular accidents (4%), infectious





Causes of death listed as “diverse”. Paper specifies that liver
disease was not primary cause of death in any included case.





Cardiovascular diseases 68%, respiratory illnesses 25%,























Road traffic Accidents (n = 35), poisoning (n = 5), hanging (n = 3),
suspicious death (n = 1), Myocardial infarction (n = 2), drowning







To corroborate our observation of increased levels of chronic hepatic pathology in
COVID-19 patients, we decided to interrogate patient LFT results for all consecutive
COVID-19-positive inpatients, for whom we could obtain admission LFT data (alanine
transaminase (ALT) and albumin, alkaline phosphatase (ALP)), length of hospital stay
and survival data (n = 276; average age 71 years; 109 (39%) female; 167 (61%) male).
Of the admitted patients, 88 (32%) died in hospital and, of these, 62 (70%) were male;
however, there was no overlap between patients dying in this cohort and the autopsy
cohort described above. Only admission LFT blood sample data was used as we reasoned
that, at later time points, there would be a greater risk that LFT abnormalities might
be confounded by SARS-CoV-2 infection rather than indicating any underlying chronic
pathology. Of the 276 patients, 258 (93%) had at least one abnormal LFT parameter. We
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used albumin (half-life: 20 days) as a marker of long-term liver (or renal) disease and ALT
(half-life: 47 h) as an indicator of more recent changes to hepatic function [77]. We compared
the albumin and ALT levels between the patient groups with four different lengths of stay
in hospital (<7 days, 7–13 days, 14–21 days and >21 days), demonstrating a statistically
significant decrease in the albumin levels, with poorer outcomes (i.e., increasing lengths
of hospital stay and death) (p = 0.000012) (Table 5). However, no statistically significant
difference was found in the ALT levels between these groups (p = 0.73), indicating that
the admission albumin level was a predictor of COVID-19 severity. However, higher ALT
levels showed a stronger correlation with those patients who went on to die in hospital,
compared with those who survived (p = 0.0135), than did lower albumin levels (p = 0.081).
This corroborates the fact that ALT levels are likely to act as a marker of acute pathology
related to SARS-Co-V2 infection, while albumin is more likely to indicate pre-existing
pathological conditions that act as risk factors for more severe SARS-Co-V2 infection.
Table 5. Results of analysis of two post-mortem liver function tests, albumin and alanine aminotransferase (ALT), as a














































<7 38/54 (70.4%) 0.00043 29 ± 3.9 16/54 (26.6%) 0.42 76.8 ± 45.3
7–13 46/52 (88.5%) 0.020 27.8 ± 4.1 13/52 (25.0%) 0.55 93.7 ± 59.8










Deceased 80/88 (90.9%) 24.6 ± 5.8 14/88 (15.9%) 101.1 ± 88.7






Herein we report the findings of 22 PM examinations carried out on confirmed or
suspected COVID-19 cases. Of the 19 cases in which the liver was examined, there was
a striking over-representation of hepatic pathology, with at least one likely longstanding
liver abnormality in each case. There were several limitations to this observational study,
including the small sample size, its limitation to those whose autopsies were requested
by a coroner and its limitation to two Coronial jurisdictions, which may mean that this
cohort is not necessarily representative of all deaths due to COVID-19 in the U.K. Moreover,
the autopsies were carried out by one pathologist, which increased the risk of reporting
bias. Furthermore, a subsequent literature review identified the widespread reported
multisystemic effects of COVID-19 documented thus far in PM studies. We used pre-
COVID-19 pandemic PM studies with a range of causes of death to gain an indication of the
baseline level of hepatic pathology amongst the global population. Although our findings
were restricted by the limitations of literature reviews, such as the quality of evidence and
Diagnostics 2021, 11, 1703 16 of 21
biases such as selection and publication bias, our results indicate a higher prevalence of
hepatic pathology in individuals dying from COVID-19 than from other causes. On the
basis of the observational data reported, no causal inference can be made as there were
potential confounding factors in our comparison with pre-pandemic autopsy data, such as
age, ethnicity and geographical and socioeconomic background. However, our findings
indicate that liver disease may be a more important risk factor for COVID-19 mortality
than previously thought, which should encourage further studies to explore this possible
link with a larger and globally representative sample size.
To corroborate our findings in autopsy data indicating that chronic liver disease is a
significant risk factor for mortality in COVID-19, we analysed admission LFT data. Admis-
sion albumin levels, a crude and incompletely specific indicator of chronic liver disease,
predicted more severe SARS-Co-V2 infection, with longer hospital admission. This was in
agreement with previous studies [78–80], including those confirming hypoalbuminaemia
as an independent predictive factor for mortality in COVID-19 patients [79]. As a com-
parator, we analysed ALT levels, which indicated much more acute hepatic pathology,
and found that admission ALT did not predict the length of hospital admission. However,
commensurate with their ability to indicate acute pathology, raised admission ALT levels
correlated with the risk of mortality, presumably acting as a biomarker of widespread
direct, or indirect, COVID-19-mediated injury to the organs, including the liver.
Emerging evidence supports the hypothesis that liver disease of all stages, ranging
from steatosis to cirrhosis, predisposes affected patients to severe SARS-CoV-2 infection.
Non-alcoholic fatty liver disease (NAFLD), also known as metabolic-associated fatty liver
disease (MAFLD), is thought to be the most common cause of liver disease in the western
world, causing a spectrum of hepatic dysfunction ranging from to steatosis to cirrhosis [81].
A recent systematic review identified MAFLD as being associated with a four-to-sixfold
increase in the risk of severe COVID-19 [82] and a further study reports that MAFLD
independently increases the risk of severe COVID-19, after adjusting for the effect of
sex, obesity and diabetes, with the risk increasing in line with the degree of resultant
liver fibrosis [83]. Univariate analysis of UK Biobank data confirms that liver fat content
correlates with the risk of symptomatic COVID-19 [84]. While it might be argued that
liver fat content is simply a surrogate marker for overweight individuals, the same study
showed that overweight individuals were only at increased risk of more severe COVID-19
if they demonstrated concurrent raised hepatic fat levels [84], suggesting liver dysfunction
may form part of the mechanism by which obesity confers COVID-19 risk.
Hepatic dysfunction due to ethanol consumption in alcoholic liver disease (ALD) also
causes a spectrum of liver disease, ranging from steatosis to cirrhosis [85], and appears
to predispose affected patients to severe COVID-19 [86]. Alcohol consumption disrupts
both the innate and adaptive immune system and increases susceptibility to both viral and
bacterial infections [87]. Moreover, like MAFLD, ALD often co-exists with other COVID-19
risk factors, such as metabolic syndrome; occasionally, ALD patients may be immunocom-
promised as a result of alcohol-related hepatitis treatment with corticosteroids [88].
The exact mechanisms by which liver dysfunction predisposes affected patients to
severe COVID-19 are unknown but may be immunological. Cirrhosis dysregulates both
innate and adaptive immunity, increasing susceptibility to acute inflammatory reactions
and subsequent exaggerated courses [89]. It has been reported as an independent risk
factor for mortality in patients with Acute Respiratory Distress Syndrome (ARDS) [90] and
a predictor of adverse outcomes in Systemic Inflammatory Response Syndrome (SIRS) [91],
both ARDS and SIRS being potential COVID-19 sequelae [12,92]. Importantly, multivariable
adjusted models have been used to demonstrate that liver fat levels correlate with multiple
markers of inflammation and oxidative stress, whereas obese patients with normal livers,
who may not be at increased risk of severe COVID-19 [84], are characterised by lower
pro-inflammatory cytokine levels [93].
One other possibility is that hepatic inflammation or dysfunction may play a role
in hampering interferon (IFN)-mediated anti-viral responses [94,95]. Neutralising IgG
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auto-antibodies against type 1 IFNs have been found in individuals with severe COVID-19,
but not in those with mild disease [96]. These antibodies prevented IFNs from blocking
SARS-CoV-2 cell entry in vitro and reduced the levels of circulating IFN in vivo to low
or undetectable levels. For example, when IFN-alpha was used in the treatment of viral
hepatitis, its efficacy was diminished in alcohol-dependent patients; this was hypothesised
to have been the result of ALD-mediated down-regulation of IFN-alpha signalling path-
ways, although anti-IFN antibodies have not been specifically sought in this setting [97].
Trials of IFN as a COVID-19 therapy have thus far yielded uncertain results [98]. The link
between hepatic dysfunction and IFN dysregulation in the context of severe COVID-19
therefore requires further investigation, as this relationship has mechanistic, prognostic
and therapeutic implications.
In summary, our study indicates that liver disease is a potentially important COVID-
19 risk factor that may be undetected prior to autopsy. Whilst the global prevalence
of ALD is difficult to estimate, steatosis is thought to develop in over 90% of heavy
drinkers [99] and metanalysis estimates the global prevalence of MAFLD at approximately
25% [100]. However, since the early stages of both alcoholic and non-alcoholic fatty
liver disease are usually asymptomatic [88], neither disease is as widely recognised or
as frequently investigated as other commonly cited COVID-19 risk factors, such as age,
obesity and hypertension. Given its high prevalence, its potential role in mediating and/or
predisposing affected patients to severe COVID-19 and its potentially asymptomatic [88]
and reversible [101] nature in the early stages, greater emphasis should be placed on
screening for liver disease when considering public health measures, such as shielding and
risk stratification.
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